Sökning: (WFRF:(Strand Sven Erik)) > 188Re-ZHER2:V2, a p...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07208naa a2200829 4500 | |
001 | oai:lup.lub.lu.se:61596623-f0c1-475d-9288-9fe43d45015b | |
003 | SwePub | |
008 | 221116s2014 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:kth-157017 | |
009 | oai:DiVA.org:uu-211593 | |
024 | 7 | a https://lup.lub.lu.se/record/61596623-f0c1-475d-9288-9fe43d45015b2 URI |
024 | 7 | a https://doi.org/10.2967/jnumed.114.1401942 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1570172 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2115932 URI |
040 | a (SwePub)lud (SwePub)kthd (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Altai, Mohamedu Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)mohal988 |
245 | 1 0 | a 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment |
264 | c 2014-10-02 | |
264 | 1 | b Society of Nuclear Medicine,c 2014 |
500 | a QC 20141205 | |
520 | a UNLABELLED: Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.METHODS: ZHER2:V2 was labeled with (188)Re using a gluconate-containing kit. Targeting of HER2-overexpressing SKOV-3 ovarian carcinoma xenografts in nude mice was studied for a dosimetry assessment.RESULTS: Binding of (188)Re-ZHER2:V2 to living SKOV-3 cells was demonstrated to be specific, with an affinity of 6.4 ± 0.4 pM. The biodistribution study showed a rapid blood clearance (1.4 ± 0.1 percentage injected activity per gram [%ID/g] at 1 h after injection). The tumor uptake was 14 ± 2, 12 ± 2, 5 ± 2, and 1.8 ± 0.5 %IA/g at 1, 4, 24, and 48 h after injection, respectively. The in vivo targeting of HER2-expressing xenografts was specific. Already at 4 h after injection, tumor uptake exceeded kidney uptake (2.1 ± 0.2 %IA/g). Scintillation-camera imaging showed that tumor xenografts were the only sites with prominent accumulation of radioactivity at 4 h after injection. Based on the biokinetics, a dosimetry evaluation for humans suggests that (188)Re-ZHER2:V2 would provide an absorbed dose to tumor of 79 Gy without exceeding absorbed doses of 23 Gy to kidneys and 2 Gy to bone marrow. This indicates that future human radiotherapy studies may be feasible.CONCLUSION: (188)Re-ZHER2:V2 can deliver high absorbed doses to tumors without exceeding kidney and bone marrow toxicity limits. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
653 | a Animals | |
653 | a Antibodies/chemistry | |
653 | a Cell Line, Tumor | |
653 | a Chelating Agents/chemistry | |
653 | a Drug Evaluation, Preclinical | |
653 | a Female | |
653 | a Gluconates/chemistry | |
653 | a Humans | |
653 | a Mice | |
653 | a Mice, Nude | |
653 | a Oligopeptides/chemistry | |
653 | a Ovarian Neoplasms/drug therapy | |
653 | a Peptides/chemistry | |
653 | a Radiation Dosage | |
653 | a Radioisotopes/therapeutic use | |
653 | a Radiometry | |
653 | a Radiopharmaceuticals | |
653 | a Receptor, ErbB-2/chemistry | |
653 | a Rhenium/chemistry | |
653 | a Xenograft Model Antitumor Assays | |
653 | a HER2 | |
700 | 1 | a Wållberg, Helenau KTH,KTH Royal Institute of Technology,Proteinteknologi4 aut0 (Swepub:kth)u1527tt1 |
700 | 1 | a Honarvar, Hadisu Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)hadho340 |
700 | 1 | a Strand, Joannau Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)joast981 |
700 | 1 | a Orlova, Annau Uppsala universitet,Uppsala University,Plattformen för preklinisk PET4 aut0 (Swepub:uu)annaorlo |
700 | 1 | a Varasteh, Zohrehu Uppsala universitet,Uppsala University,Plattformen för preklinisk PET4 aut0 (Swepub:uu)zohva473 |
700 | 1 | a Sandström, Mattiasu Uppsala universitet,Uppsala University,Uppsala University Hospital,Enheten för medicinsk strålfysik,Enheten för nuklearmedicin och PET4 aut0 (Swepub:uu)masan637 |
700 | 1 | a Löfblom, Johnu KTH,KTH Royal Institute of Technology,Proteinteknologi4 aut0 (Swepub:kth)u1z7cgkl |
700 | 1 | a Larsson, Eriku Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)radf-ela |
700 | 1 | a Strand, Sven-Eriku Lund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,Systemic Radiation Therapy Group,Lund University Research Groups4 aut0 (Swepub:lu)rafy-ses |
700 | 1 | a Lubberink, Marku Uppsala universitet,Uppsala University,Uppsala University Hospital,Enheten för nuklearmedicin och PET,Avdelningen för sjukhusfysik4 aut0 (Swepub:uu)marklubb |
700 | 1 | a Ståhl, Stefanu KTH,KTH Royal Institute of Technology,Proteinteknologi,Uppsala University, Sweden4 aut0 (Swepub:kth)u1svy8i4 |
700 | 1 | a Tolmachev, Vladimiru Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)vladtolm |
710 | 2 | a Uppsala Universityb Enheten för biomedicinsk strålningsvetenskap4 org |
773 | 0 | t Journal of nuclear medicine : official publication, Society of Nuclear Medicined : Society of Nuclear Medicineg 55:11, s. 8-1842q 55:11<8-1842x 0161-5505x 1535-5667x 2159-662X |
773 | 0 | t Journal of Nuclear Medicined : Society of Nuclear Medicineg 55:11, s. 8-1842q 55:11<8-1842x 2159-662X |
856 | 4 | u http://dx.doi.org/10.2967/jnumed.114.140194x freey FULLTEXT |
856 | 4 | u http://jnm.snmjournals.org/content/55/11/1842.full.pdf |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:675121/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint |
856 | 4 8 | u https://lup.lub.lu.se/record/61596623-f0c1-475d-9288-9fe43d45015b |
856 | 4 8 | u https://doi.org/10.2967/jnumed.114.140194 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-157017 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211593 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy